Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 5/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.44 |
| ▸ | MMP1 | P03956 | 2/20 | 0.44 |
| ▸ | MMP9 | P14780 | 2/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863929 | 0.94 | PGR (0.54) | LTA4HPGRKCNH2HTTMCHR1 | |
| SCHEMBL5863991 | 0.93 | NR3C1 (0.50) | LTA4HPGRKCNH2HTTMCHR1 | |
| SCHEMBL5864005 | 0.90 | LTA4H (0.47) | LTA4HKCNH2HTTMCHR1ESR1 | |
| SCHEMBL5863875 | 0.90 | LTA4H (0.47) | LTA4HKCNH2MCHR1ESR1ESR2 | |
| SCHEMBL5863789 | 0.90 | LTA4H (0.53) | LTA4HKCNH2HTTMCHR1ESR1 | |
| SCHEMBL5864250 | 0.87 | MMP1 (0.51) | LTA4HESR1ESR2MMP1MMP9 | |
| SCHEMBL5863843 | 0.87 | NR3C1 (0.50) | LTA4HKCNH2HTTMCHR1ESR1 | |
| SCHEMBL5863649 | 0.87 | MMP1 (0.51) | LTA4HKCNH2HTTESR1ESR2 | |
| SCHEMBL5863389 | 0.87 | MMP1 (0.57) | LTA4HPGRHTTESR1ESR2 | |
| SCHEMBL5863911 | 0.87 | MMP1 (0.48) | LTA4HKCNH2ESR1ESR2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053212-B2 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | GHSR, GPER1, SSTR1 | LTA4H 1687/4885PGR 54/4885KCNH2 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.